How We Do It

Sophisticated science generating robust results

Excellent science is at the heart of everything we do at Atturos. Using state-of-the-art equipment and advanced proteomics methods, we are consistently developing (and improving) our methods to identify biomarkers for various diseases. Mass spectrometry has proven to be a robust platform, and the best statistical approaches have been used to build an established clinical laboratory. Targeted MS analysis using Multiple Reaction Monitoring (MRM) allows us to detect and quantify ultra-low protein concentrations. This method also has the advantages of high specificity, sensitivity, multiplexing capability, and precision over other commonly used molecular diagnostic methods. The end result of this is an easy to interpret score to help clinicians and patients make informed decisions about their healthcare. The Atturos team have spent many years researching biomarker discovery and are committed to converting their efforts into clinically utilised tests. The technical (and commercial) feasibility testing of the OCProDx assay is supported by the EU Horizon 2020 SME Instrument phase 1 grant.